Dynamic whole-body imaging for cancer diagnosis and treatment monitoring
Dynamic Whole-body PET/CT Imaging in Clinical Oncology
This study is testing a new way of using whole-body imaging to see if it can improve how doctors diagnose cancer and monitor treatment in patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Geneva Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Geneva) |
| Trial ID | NCT06424873 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to enhance cancer diagnosis and treatment monitoring by merging whole-body and dynamic PET/CT imaging techniques. Participants will undergo PET/CT scans using FDG or FES to achieve robust quantitative imaging in clinically feasible scan times. The study seeks to improve the understanding of how PET probes distribute in the body, which could lead to better diagnostic and prognostic capabilities in oncology. By addressing the limitations of static PET data, this approach could fundamentally change routine clinical practices in cancer care.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who are clinically indicated for whole-body PET evaluation.
Not a fit: Patients under 18 years of age and pregnant women will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the accuracy of cancer diagnosis and treatment monitoring.
How similar studies have performed: While the integration of dynamic imaging techniques is a novel approach, similar studies have shown promise in enhancing imaging capabilities in oncology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients clinically indicated for whole-body PET evaluation. 2. Patient must agree to lie still in the camera. 3. Patient must be able to comply with study procedures. 4. Patient must be able to provide informed consent. Exclusion Criteria: 1. Patients \< 18 years of age. 2. Pregnant women are excluded.
Where this trial is running
Geneva
- Geneva University Hospitals — Geneva, Switzerland (Recruiting)
Study contacts
- Study coordinator: Valentina Garibotto, Pr
- Email: valentina.garibotto@hcuge.ch
- Phone: +41223727252
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.